Neurame

Neurame is a pre-clinical stage biotechnology company focused on developing novel therapies for neurodegenerative diseases by leveraging a proprietary protein disaggregase platform. The company's core technology centers on engineered versions of the yeast protein Hsp104, which are designed to selectively dissolve toxic protein aggregates associated with conditions such as ALS, Parkinson's, and Alzheimer's. By targeting the underlying protein misfolding pathology, Neurame aims to restore cellular health and halt disease progression in patients with limited treatment options. The company was founded by leading researchers in the field of protein folding and neurodegeneration from the University of Pennsylvania.